FemtoMag, Inc. develops biosensor technologies utilizing magnetic nanoparticle reporters for the ultrasensitive quantitative detection of biomarkers in medical diagnostics. Their platform significantly enhances the sensitivity of lateral flow assays, improving cancer diagnostics and treatment monitoring while addressing challenges such as sample turbidity and autofluorescence.
Funding
Funding not disclosed
Founders
Product
Problem
Current lateral flow assays (LFA) often lack the sensitivity needed for early or precise detection of biomarkers, particularly in complex samples where turbidity, autofluorescence, and other factors can interfere with accurate results. Existing gold nanoparticle reporters also offer limited signal amplification, hindering the detection of low-abundance targets.
Solution
FemtoMag, Inc. is developing a biosensor platform that enhances the sensitivity of lateral flow assays by utilizing magnetic nanoparticle reporters. This technology aims to improve the quantitative detection of biomarkers for applications such as cancer diagnostics, treatment monitoring, and infectious disease diagnostics. The femtoMag platform integrates magnetic sensing to overcome limitations associated with traditional LFA methods, offering increased sensitivity and reduced interference from sample characteristics.
Target Audience
The primary target audience includes medical diagnostic companies, clinical laboratories, and researchers involved in cancer diagnostics, treatment monitoring, and infectious disease diagnostics.
Features
- Utilizes magnetic nanoparticle reporters for enhanced signal amplification in LFA.
- Integrates giant magnetoresistive, inductive, and magnetoelectric sensors for biomarker detection.
- Aims to achieve 1-2 orders of magnitude greater sensitivity compared to gold nanoparticle-based LFA.
- Designed to mitigate interference from sample turbidity, autofluorescence, photobleaching, and enzyme inhibitors.